edema, fever, analgesia, organ hypoxia; thrombin-induced platelet aggregation; or protozoal diseases.

13. The use of any one of claims 1 to 12, wherein the pirfenidone is to be administered at a total daily dose of 1 mg/kg to 40 mg/kg per day.

14. The use of any one of claims 1 to 12, wherein the pirfenidone is to be administered at a total daily dosage of at least 1800 mg.

15. The use of any one of claims 1 to 12, wherein the pirfenidone is to be administered at a total daily dosage of 2400 mg or 2403 mg.

16. The use of any one of claims 1 to 12, wherein each dose of pirfenidone to be administered is 801 mg.

17. The use of any one of claims 1 to 16, wherein pirfenidone is to be administered three times a day.

18. The use of any one of claims 1 to 17, wherein pirfenidone is to be administered with food.

19. A package or kit comprising (a) pirfenidone, optionally in a container, and (b) a package insert, package label, instructions or other labeling comprising avoiding or discontinuing concomitant use or co-administration of a strong inducer of cytochrome P450 1A2 (CYP1A2), and optionally according to any one of claims 1-18.